Praxis’ epilepsy drug reduces seizures by 46% in pediatric patients in Phase 2 study

Praxis Precision Medicines released another batch of topline data from its epilepsy program on Tuesday, this time from the Phase 2 EMBOLD study investigating relutrigine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the

October 27, 2024

Insulet CFO leaves for 3M health spinoff

Name: Wayde McMillan New title: CFO of 3M Health Care Previous title: CFO of Insulet Wayde McMillan plans to step down as CFO and treasurer

October 4, 2023

Amgen scores FDA approval for Stelara biosimilar – Pharmaceutical Technology

The interchangeable Stelara biosimilar was approved for adults with multiple inflammatory diseases including psoriatic arthritis. Credit: sompong_tom via Getty Images. Amgen’s interchangeable biosimilar version of

November 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.